Feb 27, 2023
Use of systemic antibiotics in patients with COVID-19 in Colombia. A cross-sectional study
- Jorge Machado Alba1
- 1Universidad Tecnologica de Pereira
External link: https://doi.org/10.3390/antibiotics12020252
Protocol Citation: Jorge Machado Alba 2023. Use of systemic antibiotics in patients with COVID-19 in Colombia. A cross-sectional study. protocols.io https://dx.doi.org/10.17504/protocols.io.rm7vzbk5xvx1/v1
Manuscript citation:
Valladales-Restrepo LF, Delgado-Araujo AC, Echeverri-Martínez LF, Sánchez-Ríos V, Machado-Alba JE, Use of Systemic Antibiotics in Patients with COVID-19 in Colombia: A Cross-Sectional Study. Antibiotics 12(2). doi: 10.3390/antibiotics12020252
License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Protocol status: Working
We use this protocol and it's working
Created: December 14, 2022
Last Modified: February 27, 2023
Protocol Integer ID: 73974
Keywords: antibiotics prescription patterns for patient, use of systemic antibiotic, antibiotics prescription pattern, systemic antibiotic, most of the antibiotic, antibiotic, antibiotics from the watch group, antibiotics despite evidence, clinics in colombia, most of the patient, clarithromycin, intensive care unit, patient, median age of the patient
Abstract
Abstract
Antibiotics are frequently prescribed to patients with COVID-19. The aim was to determine the pattern of use of systemic antibiotics in a group of patients diagnosed with COVID-19 in Colombia in the 2020-2022 period. This was a descriptive cross-sectional study designed to identify antibiotics prescription patterns for patients diagnosed with COVID-19 treated in 8 clinics in Colombia. The AWaRe tool of the World Health Organization (WHO) was used to classify the antibiotics. A total of 10,916 patients from 181 cities were included. The median age of the patients was 57 years, and 56.4% were men. A total of 29.7% of the patients required intensive care unit (ICU) care, and 20.2% required invasive mechanical ventilation. A total of 57.5% received antibiotics, especially ampicillin/sulbactam (58.8%) and clarithromycin (47.9%). Most of the antibiotics were classified as Watch (65.1%), followed by Access (32.6%) and Reserve (2.4%). Men (OR:1.29; 95% CI:1.17-1.43), older adults (OR:1.67; 95%CI:1.48-1.88), patients with dyspnea at admission (OR:1.26; 95%CI:1.13-1.41), rheumatoid arthritis (OR:1.94; 95%CI:1.17-3.20), and high blood pressure (OR:1.45; 95%CI: 1.29-1.63), patients treated in-hospital (OR:5.15; 95%CI: 4.59-5.77), patients admitted to the ICU (OR:10.48; 95%CI:8.82-12.45), patients treated with systemic glucocorticoids (OR:3.60; 95%CI:3.21-4.03) and vasopressors (OR:2.10; 95% CI: 1.60-2.75), and patients who received invasive mechanical ventilation (OR: 2.37; 95% CI: 1.82-3.09) were more likely to receive a systemic antibiotic.Most of the patients diagnosed with COVID-19 received antibiotics despite evidence showing that bacterial coinfection is rare. Antibiotics from the Watch group predominated, a practice that goes against WHO recommendations.
Attachments
Troubleshooting